• Skip to primary navigation
  • Skip to main content
English Spainish
My Account
LaRed Home

LaRed

Mexican Emerging Infectious Disease Clinical Research Network

  • About Us
    • About Us
    • Leadership
    • Partners
  • Studies
    • ACTT
    • CN-SARI
    • FLU-IVIG
    • FLU-PRO
    • HEALTHY COHORT
    • INSIGHT-011
    • ILI 2014
    • ILI 002
    • IRC 003
    • NTZ-SARI
    • SPRINT-SARI
    • ZIK 01
    • InVITE
    • OTAC
  • News and Events
  • Resources
    • Publications
    • Regulations / Policies
  • Contact Us
    • Contact Us
    • Sites

ACTT

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalized adults with COVID-19: a double-bind, randomized, placebo-controlled, phase 3 trial

April 9, 2022 by

https://www.redmexei.mx/storages/2022/04/ACTT-20-0006_-IFN.pdf

Remdesivir for the Treatment of Covid-19 — Final Report

April 2, 2022 by

https://www.redmexei.mx/storages/2022/04/Remdesivir-for-the-Treatment-of-Covid-19.pdf

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

April 2, 2022 by

https://www.redmexei.mx/storages/2022/04/Baricitinib-plus-Remdesivir-for-Hospitalized-Adults-with-Covid-19.pdf

Footer Logo

The Mexican Emerging Infectious Disease Clinical Research Network (LaRed)

Address:
Coscomate 71, Int. 1A, Colonia Toriello Guerra, Alcaldía Tlalpan, CP 14050 CdMx
Phone:
(+52) 55 5573 0734, (+52) 55 5162 5552

Main Navigation


  • Home
  • About
  • Studies
  • News & Events
  • Resources
  • Contact

Site Help


  • Sitemap
  • Privacy
  • Terms Of Use
Copyright ©2019 All rights reserved | LaRed

Multilingual WordPress with WPML